Clinical Trials Logo

Clinical Trial Summary

This study will investigate the use of hyperpolarized (HP) carbon-13 (13C) alpha-ketoglutarate (aKG) (HP 13C-aKG) to characterize tumor burden in patients with isocitrate dehydrogenase (IDH) mutant glioma.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To define the most appropriate imaging parameters for obtaining hyperpolarized 13C-aKG from patients with IDH mutant glioma. II. To assess the safety and feasibility of hyperpolarized 13C-aKG magnetic resonance (MR) metabolic imaging as a new and unique tool for evaluating tumor burden in patients with IDH mutant glioma. OUTLINE: This imaging study will involve one MR scan with the administration of HP 13C-aKG. Patients will be assigned to one of 2 cohorts: Cohort 1 (Participants with IDH mutant glioma for sequence development) and Cohort 2 (Participants with recurrent IDH mutant glioma before receiving surgical resection). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05851378
Study type Interventional
Source University of California, San Francisco
Contact Wendy Ma
Phone (415) 514-4418
Email Wendy.Ma@ucsf.edu
Status Recruiting
Phase Early Phase 1
Start date April 11, 2023
Completion date April 30, 2026